VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
Key Highlights
- ➤Strategic collaboration pairs Chemveda compound development with VivoSim human-tissue screening
- ➤VivoSim screens more than 20 compounds in two weeks
- ➤NAMkind Liver model predicted drug-induced liver injury with 91% accuracy
- ➤NAMkind Liver model achieved 90% sensitivity and 95% specificity
- ➤Joint offering launches to Chemveda’s global clients; first programs expected Q4, 2026
Expert Statements
Keith Murphy, Executive Chairman of VivoSim
“AI has handed our industry a firehose producing new molecules. What it hasn’t handed us is a way to know which of them will work and which may harm patients”
Keith Murphy, Executive Chairman of VivoSim
“That is exactly the problem VivoSim was built to solve. With Chemveda making AI-designed compounds at world-class speed and quality, and VivoSim testing them in real human tissue, our partners will know in weeks, not years, which molecules deserve to move forward. This is what drug discovery looks like when we replace guesswork with human-relevant results.”
Dr. Bheema Rao Paraselli, Founder, President and Chief Executive Officer of Chemveda Life Sciences
“Chemveda was founded to shorten the distance between an idea and a molecule, and AI is now compressing that distance faster than anyone expected”
Dr. Bheema Rao Paraselli, Founder, President and Chief Executive Officer of Chemveda Life Sciences
“Our clients need a safety answer that is just as fast and far more human-relevant than what the industry has relied on. By combining Chemveda’s discovery, medicinal and process chemistry capabilities with VivoSim’s NAMkind™ models, we can create a tighter feedback loop between molecular design, synthesis and human-relevant biological data. That means our clients can not only identify liabilities earlier, but also put those insights directly back into the hands of the chemists designing the next molecule. Together, we are turning design-make-test into design-make-know.”
SAN DIEGO and HYDERABAD, India, Nov. 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (“VivoSim” or “Company”), a provider of AI-enabled New Approach Methodologies (NAMs) for preclinical safety, and Chemveda Life Sciences (“Chemveda”), an integrated contract research, development and manufacturing organization (CRDMO), today announced a strategic collaboration to test and screen AI-derived drug compounds in VivoSim’s human-relevant NAMkind™ 3D tissue models.
Artificial intelligence has changed how fast new drugs can be imagined. Generative models can now propose thousands of novel molecules in the time it once took to design a handful. What has not kept pace is the ability to know, early, which of those molecules will be safe and effective in people. Liver and gastrointestinal toxicity remain among the most common reasons promising drugs fail in the clinic, often after years of work and hundreds of millions of dollars.
Get started
Create a free account to read the full story.